Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis

di Vansteenkiste, Johan
Pubblicato in ESMO Open (2017)

Immunotherapy in lung cancer

di Vansteenkiste, Johan F
Pubblicato in ESMO Open (2018)

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer

di Vansteenkiste, Johan F
Pubblicato in ESMO Open (2018)

Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?

di Wauters, Els, Vansteenkiste, Johan
Pubblicazione 2014

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia

di Wauters, Isabelle, Pat, Karin, Vansteenkiste, Johan
Pubblicazione 2006

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

di Deslypere, Griet, Gullentops, Dorothée, Wauters, Els, Vansteenkiste, Johan
Pubblicato in Ther Adv Med Oncol (2018)

Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations

di Vliegen, Liesbet, Dooms, Christophe, De Kelver, Wim, Verbeken, Eric, Vansteenkiste, Johan, Vandenberghe, Peter
Pubblicato in Diagn Pathol (2015)

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent

di Pirker, Robert, Pirolli, Melissa, Quigley, Jane, Hulnick, Scott, Legg, Jason, Collins, Helen, Vansteenkiste, Johan
Pubblicazione 2012

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

di Kreuter, Michael, Vansteenkiste, Johan, Griesinger, Frank, Hoffmann, Hans, Dienemann, Hendrik, De Leyn, Paul, Thomas, Michael
Pubblicazione 2007

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-...

di Vansteenkiste, Johan, Hedenus, Michael, Gascon, Pere, Bokemeyer, Carsten, Ludwig, Heinz, Vermorken, Jan, Hamilton, Lisa, Bridges, Ken, Pujol, Beatriz
Pubblicazione 2009

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

di Manegold, Christian, Vansteenkiste, Johan, Cardenal, Felipe, Schuette, Wolfgang, Woll, Penella J., Ulsperger, Ernst, Kerber, Anne, Eckmayr, Josef, von Pawel, Joachim
Pubblicazione 2012

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort st...

di Hantson, Inge, Dooms, Christophe, Verbeken, Eric, Vandenberghe, Peter, Vliegen, Liesbet, Roskams, Tania, Borght, Sara Vander, Nackaerts, Kris, Wauters, Isabelle, Vansteenkiste, Johan
Pubblicazione 2014

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer

di Umelo, Ijeoma, Noeparast, Amir, Chen, Gang, Renard, Marleen, Geers, Caroline, Vansteenkiste, Johan, Giron, Philippe, De Wever, Olivier, Teugels, Erik, De Grève, Jacques
Pubblicato in Oncotarget (2015)

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patient...

di Ciardiello, Fortunato, Adams, Richard, Tabernero, Josep, Seufferlein, Thomas, Taieb, Julien, Moiseyenko, Vladimir, Ma, Brigette, Lopez, Gustavo, Vansteenkiste, Johan F., Esser, Regina, Tejpar, Sabine
Pubblicato in Oncologist (2016)

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of...

di Rizvi, Naiyer, Barlesi, Fabrice, Brahmer, Julie, Felip, Enriqueta, Forde, Patrick, Garassino, Marina, Goldberg, Sarah, Vansteenkiste, Johan, Jarkowski, Anthony, McIntosh, Stuart, Zhao, Luping, Antonia, Scott
Pubblicato in J Immunother Cancer (2015)

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue

di Reynders, Kobe, Wauters, Els, Moisse, Matthieu, Decaluwé, Herbert, De Leyn, Paul, Peeters, Stéphanie, Lambrecht, Maarten, Nackaerts, Kristiaan, Dooms, Christophe, Janssens, Wim, Vansteenkiste, Johan, Lambrechts, Diether, De Ruysscher, Dirk
Pubblicato in Radiat Oncol (2018)

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

di Harvey, R. Donald, Aransay, Noemi Reguart, Isambert, Nicolas, Lee, Jong‐Seok, Arkenau, Tobias, Vansteenkiste, Johan, Dickinson, Paul A., Bui, Khanh, Weilert, Doris, So, Karen, Thomas, Karen, Vishwanathan, Karthick
Pubblicato in Br J Clin Pharmacol (2018)

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasi...

di De Grève, Jacques, Van Meerbeeck, Jan, Vansteenkiste, Johan F., Decoster, Lore, Meert, Anne-Pascale, Vuylsteke, Peter, Focan, Christian, Canon, Jean-Luc, Humblet, Yves, Berchem, Guy, Colinet, Benoit, Galdermans, Danny, Bosquée, Lionel, Vermeij, Joanna, Dewaele, Alex, Geers, Caroline, Schallier, Denis, Teugels, Erik
Pubblicato in PLoS One (2016)

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Cli...

di Jänne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crinò, Lucio, Orlov, Sergey, Blackhall, Fiona, Wolf, Juergen, Garrido, Pilar, Poltoratskiy, Artem, Mariani, Gabriella, Ghiorghiu, Dana, Kilgour, Elaine, Smith, Paul, Kohlmann, Alexander, Carlile, David J., Lawrence, David, Bowen, Karin, Vansteenkiste, Johan
Pubblicato in JAMA (2017)

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

di Garassino, Marina Chiara, Cho, Byoung-Chul, Kim, Joo-Hang, Mazières, Julien, Vansteenkiste, Johan, Lena, Hervé, Jaime, Jesus Corral, Gray, Jhanelle E, Powderly, John, Chouaid, Christos, Bidoli, Paolo, Wheatley-Price, Paul, Park, Keunchil, Soo, Ross A, Huang, Yifan, Wadsworth, Catherine, Dennis, Phillip A, Rizvi, Naiyer A
Pubblicato in Lancet Oncol (2018)